drugset / Trial / NCT01918332

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

NCT01918332

Phase 3 Completed 168 enrolled LG Life Sciences
RandomizedFactorialTriple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Valsartan Small molecule 160 mg Oral